Radio Episodes
4/12/2022
C. diff. Spores and More
Our guests from Seres Therapeutics shared the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). Listen Now
6/29/2021
C. diff. Spores and More
Our guests from Seres Therapeutics shared the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). Listen Now
2/16/2021
C. diff. Spores and More
Join us with our guests from Seres Therapeutics as they discuss the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. Listen Now
9/22/2020
C. diff. Spores and More
Join us with our guests from Seres Therapeutics as they discuss the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. Listen Now
8/18/2020
C. diff. Spores and More
Join us with our guests from Seres Therapeutics as they discuss the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. Listen Now